Numeral 17 — NOM-048-SSA2-2017, Para la prevención, detección, diagnóstico, tratamiento, vigilancia epidemiológica y promoción de la salud sobre el crecimiento prostático benigno (hiperplasia de la próstata) y cáncer de próstata (tumor maligno de la próstata).

17 Bibliografía

17.1 Adolfsson J. Watchful waiting and a ctive surveillance: the current position. BJU Int 2008 Jul;

102(1):10-4.

17.2 Albertsen PC, Moore DF, Shih W, et al. Impact of comorbidity on survival among men with localized

prostate cancer. J Clin Oncol 2011 Apr; 29(10):1335-41.

17.3 Attard G, Cooper CS , de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to

break? Cancer Cell 2009 Dec 8; 16(6):458-62.

17.4 Auffenberg G., Gonzalez C., Stuart J., Quentin J., Meeks W. and McVary K. An Observational

Analysis of Provider Adherence to AUA G uidelines on the Management of Benign Prostatic Hyperplasia J Urol

2014 Vol. 192, 1483-1488.

17.5 Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Screening Group. Prostate cancer

mortality after introduction of prostate specific antigen mas s screening in the Federal State of Tyrol, Austria.

Urology 2001, Sep; 58(3):417-24.

17.6 Bechis S., Otsetov A., Ge R., Olumi A. Personalized Medicine for the Management of Benign.

Prostatic Hyperplasia J Urol, 2014.

17.7 Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long -term cancer control and

recovery of sexual and urinary function ("trifecta"). Urology 2005 Nov; 66(5 Suppl):83-94.

17.8 Brenes F.J., Pérez N., Pimienta M. y Dios J.M. Recomendaciones de buena práctica clínica

Hiperplasia benigna de próstata. Abordaje SEMERGEN 2007; 23(10): 529-539.

17.9 Briganti A, Larcher A, Abdollah F, et al. Updated Nomogram Predicting Lymph Node Invasion in

Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Impo rtance

of Percentage of Positive Cores. Eur Urol 2012, Mar; 61(3):480-7.

17.10 Cartagena J., García F., Guzmán M., Quinteros M., Guzmán J. Criterios en el diagnóstico de

hiperplasia prostática benigna en pacientes que acudieron al Hospital Univalle, Rev In v Salud 2008; 3(7): 29-

33.

17.11 Chi KN, Bjartell A, Dearnaley D, et al. Castration -resistant prostate cancer: from new

pathophysiology to new treatment targets. Eur Urol. 2009, Oct; 56(4):594-605.

17.12 Chistopher S., Joyce G. Economic costs of benign pr ostatic hyperplasia in the private sector. J Urol

2005, Vol. 173, 1309 1313.

17.13 Cookson, M. et al. Castration -resistant prostate cancer: AUA guideline. American Urological

Association Education and Research, Inc. Abril 2014.

17.14 D'Amico AV, Whittingto n R, Malkowicz SB, et al. Combination of preoperative PSA level, biopsy

gleason score, percentage of positive biopsies and MRI T -stage to predict early PSA failure in men with

clinically localized prostate cancer. Urology 2000 Apr; 55 (4):572-7.

17.15 Dehesa M., Ureta S. Uroflujometría y orina residual en la evaluación de la hiperplasia prostática

benigna. Bol. Coleg Urol 2003; 18(2): 53-60.

17.16 Droz JP, Balducci L, Bolla M, et al. Background for the proposal of SIOG guidelines for the

management of prostate cancer in senior adults. Crit Rev Oncol Hematol 2010 Jan; 73 (1):68.

17.17 Epstein JI. Gleason score 2 -4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that

should not be made. Am J Surg Pathol 2000 Apr; 24 (4):477-8.

17.18 Gacci M., y co ls. A Systematic Review and Meta -analysis on the Use of Phosphodiesterase 5

Inhibitors Alone or in Combination with á -Blockers for Lower Urinary Tract Symptoms Due to Benign. Prostatic

Hyperplasia, Eur Urol. 2012, 61, 9941003.

17.19 Gosselaar C, Roobol MJ, Roemeling S, et al. The role of the digital rectal examination in subsequent

screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur

Urol 2008 Sep; 54(3):581-8.

17.20 Mottet M, et all. EAU - ESTRO – SIOG Guidelines on Prostate Cancer. 2016

17.21 Parket, C, et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and

follow-up. Ann of Oncol 26, supplement 6. Jun 2015.

17.22 Ilic D, Neuberger MM, Djulbegovic M, Dahm P. Screening for prostate cancer. Cochrane Database of

Systematic Reviews 2013, Issue 1. Art. No.: CD004720. DOI: 10.1002/14651858.CD004720.pub3

17.23 Diagnóstico y tratamiento de la hiperplasia prostática benigna. Evidencias y recomendaciones,

México, Secretaria de Salud. 2009.

17.24 Diagnóstico y tratamiento del Cáncer de Próstata en un Segundo y tercer Nivel de Atención. México.

Secretaría de Salud. 2009.

17.25 Instituto Nacional de Salud Pública, 2012. La Encuesta Nacional de Salud y Nutrición. Citado junio

disponible en: ensanut.insp.mx/

17.26 Kellogg J., Schenk J., Arnold K., Messer K., Till C., Thompson I., Kristal A. et al. For the Prostate

Cancer Prevention Trial and the Urologic Diseases in America Project Finasteride Reduces the Risk of Incident

Clinical Benign Prostatic Hyperplasia. Eur Urol. 2 01 2, 62, 234 241.

17.27 Kellogg J., Sarma A., McVary K. and Wei§ J. Obesity and Benign Prostatic Hyperplasia: Clinical

Connections, Emerging Etiological Paradigms and Future Directions J Urol 2013; 189: S102 -S106. On lin e

2014, citado junio disponible en: http://dx.doi.org/10.1016/j.juro.2012.11.029.

17.28 Lahlaidi K., Ariane M., Fontaine E. Actualités sur la prise en charge de l'hyperplasie bénigne de la

prostate. Quel adénome traiter et comment? Up -to-date on the treatm ent of benign prostatic hyperplasia.

Which adenoma to treat and how to do it? La Revue de médecine interne 35 (2014) 189195.

17.29 Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of

prostate cancer given prostate -specific antigen level, clinical stage, and biopsy Gleason score (Partin tables)

based on cases from 2000 to 2005. Urology 2007 Jun; 69(6):1095-101.

17.30 National Comprehensive Cancer Network. Prostate Cancer Clinical Practice Guidelines in Oncology.

Version 2. 2014.

17.31 Oelke M., Adler E., Marschall D., Herrmann T., Berges R. Nocturia: state of the art and critical

analysis of current assessment and treatment strategies World J Urol, 2014 32:11091117.

17.32 Oelke M., Bachmann A., Descazeaud A., Emberton M. , Gravas S., Michel M.C., Nordling J., Rosette

J. Guidelines on the Management of Male Lower Urinary Tract Symptoms (LUTS), incl. Benign prostatic

Obstruction (BPO) European Association of Urology February 2012.

17.33 European Urology Oelke M., y cols. EAU Guidelines on the Treatment and Follow -up of Non -

neurogenic Male Lower Urinary Tract Symptoms Including Benign Prostatic Obstruction 2013, 64 118140.

17.34 Oliver SE, May MT, Gunnell D. International trends in prostate -cancer mortality in the PSA -ERA'. Int

J Cancer 2001 Jun; 92(6):893-8.

17.35 Okotie OT, Roehl KA, Han M, et al Characteristics of prostate cancer detected by digital rectal

examination only. Urology 2007 Dec; 70 (6):1117-20.

17.36 Rittmaster R. 5a -reductase inhibitors in benign prostatic hype rplasia and prostate cancer risk

reduction Best Practice & Research Clinical Endocrinology & Metabolism. 2008, Vol. 22, No. 2, pp. 389402.

17.37 Roach M 3rd, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with

or without h ormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG -

ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65:965-74.

17.38 Sánchez L., Polo-de M.; Gómez F., Luengo -Mateos S. Efficacy and Safety of the Urolift System for

the Treatment of Benign Prostate Hyperplasia Symptoms: Systematic Review Actas urológicas españolas

available online 24 September 2014.

17.39 Schröder FH. Progress in understanding androgen -independent prostate cancer (AIPC): a revie w of

potential endocrine -mediated mechanisms. Eur Urol 2008 Jun; 53(6):1129 -37.

http://www.ncbi.nlm.nih.gov/pubmed/1826272 .

17.40 Secretaría de Salud. Encuesta Salud, Bienestar y Envejecimiento. Citado en junio disponible en:

http://www.cenaprece.salud.gob.mx/programas/interior/adulto/envejecimiento/EncuestaSABE.html

17.41 Seguro Social Costa Rica. Hiperplasia prostática benigna, Dirección de Medicamentos y

Terapéutica, Departamento de Farmacoepidemiología, (criterios técnicos y recomendaciones basadas en

evidencia para la construcción de guías de práctica clínica. 2005.